Literature DB >> 11868889

The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care.

Paul A Tambyah1, Valerie Knasinski, Dennis G Maki.   

Abstract

OBJECTIVE: To determine the additional direct costs of hospitalization attributable to catheter-associated urinary tract infection (CAUTI) in 1,497 newly catheterized patients.
DESIGN: Prospective observational and laboratory study.
SETTING: University hospital.
METHODS: Data were collected on risk factors for CAUTI (defined as > 10(3) colony-forming units [CFU]/mL), severity of illness, and diagnostic and therapeutic interventions in consenting newly catheterized patients. Daily urine cultures were obtained from each newly catheterized patient, but the results of these cultures were not revealed to his or her physician. During the study, one of the investigators (DGM) reviewed each patient's record and made a judgment as to which of the diagnostic tests and treatments ordered and what incremental length of stay could reasonably be ascribed to his or her CAUTI. The total hospital costs for each patient were also obtained.
RESULTS: Overall, 235 patients acquired CAUTIs during the study; most of the CAUTIs were completely asymptomatic, and only 52% were diagnosed by the patients' physicians using the hospital laboratory. Only 1 patient with a CAUTI had a secondary bloodstream infection. Thirty-three (13%) of the CAUTIs were caused by Escherichia coli; 63 (25%) by Klebsiella, Enterobacter, Citrobacter, Pseudomonas aeruginosa, or other antibiotic-resistant, gram-negative bacilli; 87 (35%) by enterococci or staphylococci; and 67 (27%) by Candida species. The 123 CAUTIs diagnosed by the hospital laboratory were judged to have been responsible for an additional $20,662 in extra costs of diagnostic tests and $35,872 in extra medication costs, a mean of $589 (median, $356) per CAUTI. CAUTIs caused by E. coli cost considerably less than infections caused by other gram-negative bacilli ($363.3 +/- $228.2 vs $690.4 +/- $783.7; P = .02) or yeasts ($821.2 +/- $2,169.9). There were less striking differences in the costs per CAUTI caused by staphylococci or enterococci ($387.1 +/- $434.8).
CONCLUSIONS: The extra direct costs associated with nosocomial CAUTI found in this prospective study, which was done in the era of managed care during the late 1990s, are substantially lower than those reported in the largest comparable studies done more than 15 years ago, most of which were retrospective, reflecting the powerful impact of cost-containment measures that are now implemented in managed care.

Entities:  

Mesh:

Year:  2002        PMID: 11868889     DOI: 10.1086/501964

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  53 in total

1.  Impact of a multidimensional infection control strategy on catheter-associated urinary tract infection rates in the adult intensive care units of 15 developing countries: findings of the International Nosocomial Infection Control Consortium (INICC).

Authors:  V D Rosenthal; S K Todi; C Álvarez-Moreno; M Pawar; A Karlekar; A A Zeggwagh; Z Mitrev; F E Udwadia; J A Navoa-Ng; M Chakravarthy; R Salomao; S Sahu; A Dilek; S S Kanj; H Guanche-Garcell; L E Cuéllar; G Ersoz; A Nevzat-Yalcin; N Jaggi; E A Medeiros; G Ye; Ö A Akan; T Mapp; A Castañeda-Sabogal; L Matta-Cortés; F Sirmatel; N Olarte; H Torres-Hernández; N Barahona-Guzmán; R Fernández-Hidalgo; W Villamil-Gómez; D Sztokhamer; S Forciniti; R Berba; H Turgut; C Bin; Y Yang; I Pérez-Serrato; C E Lastra; S Singh; D Ozdemir; S Ulusoy
Journal:  Infection       Date:  2012-06-19       Impact factor: 3.553

Review 2.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

3.  Seroepidemiology of Klebsiella pneumoniae in an Australian Tertiary Hospital and its implications for vaccine development.

Authors:  Adam W Jenney; Abigail Clements; Jacinta L Farn; Odilia L Wijburg; Andrew McGlinchey; Denis W Spelman; Tyrone L Pitt; Mary E Kaufmann; Lisa Liolios; Margaret B Moloney; Steven L Wesselingh; Richard A Strugnell
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

4.  A reliable user authentication and key agreement scheme for Web-based Hospital-acquired Infection Surveillance Information System.

Authors:  Zhen-Yu Wu; Yi-Ju Tseng; Yufang Chung; Yee-Chun Chen; Feipei Lai
Journal:  J Med Syst       Date:  2011-05-10       Impact factor: 4.460

Review 5.  Costs of hospital-acquired infection and transferability of the estimates: a systematic review.

Authors:  H Fukuda; J Lee; Y Imanaka
Journal:  Infection       Date:  2011-03-22       Impact factor: 3.553

Review 6.  Hospital epidemiology and infection control in acute-care settings.

Authors:  Emily R M Sydnor; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 7.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

8.  Bladder catheterization increases susceptibility to infection that can be prevented by prophylactic antibiotic treatment.

Authors:  Matthieu Rousseau; H M Sharon Goh; Sarah Holec; Matthew L Albert; Rohan Bh Williams; Molly A Ingersoll; Kimberly A Kline
Journal:  JCI Insight       Date:  2016-09-22

9.  Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model.

Authors:  Susan M Lehman; Rodney M Donlan
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

10.  Randomized controlled trial of silver-alloy-impregnated suprapubic catheters versus standard suprapubic catheters in assessing urinary tract infection rates in urogynecology patients.

Authors:  Ruchira Singh; Erik D Hokenstad; Sheila R Wiest; Shunaha Kim-Fine; Amy L Weaver; Michaela E McGree; Christopher J Klingele; Emanuel C Trabuco; John B Gebhart
Journal:  Int Urogynecol J       Date:  2018-08-25       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.